EGFR AMPLIFICATION Detail (hg38) (EGFR)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr7:55,086,794-55,279,321 View the variant detail on this assembly version. |
| hg38 | chr7:55,019,101-55,211,628 |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | Osimertinib,Rociletinib | D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 28202511 | Detail |
| Barrett's adenocarcinoma | B |
Prognostic
|
Supports
|
Poor Outcome | Somatic | 3 | 20840671 | Detail | |
| cervical squamous cell carcinoma | B |
Prognostic
|
Supports
|
Poor Outcome | Somatic | 3 | 21730982 | Detail | |
| head and neck squamous cell carcinoma | B |
Prognostic
|
Supports
|
Poor Outcome | Somatic | 4 | 16943533 | Detail | |
| head and neck squamous cell carcinoma | Fluorouracil,Platinum Compound,Cetuximab | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 21048039 | Detail |
| colorectal cancer | Panitumumab,Cetuximab | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24653627 | Detail |
| colorectal cancer | Cetuximab | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 18794099 | Detail |
| lung non-small cell carcinoma | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 20826716 | Detail |
| lung non-small cell carcinoma | Erlotinib,Gefitinib | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 26722081 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response... | CIViC Evidence | Detail |
| In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-spec... | CIViC Evidence | Detail |
| In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse o... | CIViC Evidence | Detail |
| The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as deter... | CIViC Evidence | Detail |
| EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recur... | CIViC Evidence | Detail |
| In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of imp... | CIViC Evidence | Detail |
| 87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed f... | CIViC Evidence | Detail |
| A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine k... | CIViC Evidence | Detail |
| In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- EGFR
- Genome
- hg38
- Position
- chr7:55,019,101-55,211,628
- Variant Type
- cnv
- Variant (CIViC) (CIViC Variant)
- AMPLIFICATION
- Transcript 1 (CIViC Variant)
- ENST00000275493.2
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/190
Genome browser